keyword
https://read.qxmd.com/read/38621948/-effects-of-tetramethylpyrazine-on-pharmacokinetics-in-plasma-and-brain-dialysate-and-neuropathic-pain-in-rat-model-of-spared-sciatic-nerve-injury
#41
JOURNAL ARTICLE
Zhi Chen, Dan-Dan DU, Ya Gao, Jun-Miao Chen, Cui-Ping Wei, Xiao-Gang Weng, Jian Sun, Xin-Yuan Wang, Zhi-Guo Wang, Mei-Yu Zhang
This study aims to explore the effects of tetramethylpyrazine(TMP) on pharmacokinetics in plasma and brain dialysate and neuropathic pain in the rat model of partial sciatic nerve injury(SNI), and to investigate the correlation between the analgesic effect of TMP and its concentrations in the plasma and brain dialysate. Male SD rats were randomized into Sham, SNI, and SNI+TMP groups. Mechanical stimulation with von frey filaments and cold spray method were employed to evaluate the mechanical sensitivity and cold sensitivity of rats...
March 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38619005/characterization-of-structural-biochemical-pharmacokinetic-and-pharmacodynamic-properties-of-the-lsd1-inhibitor-bomedemstat-in-preclinical-models
#42
JOURNAL ARTICLE
Sumer Jasmine, Adel Mandl, Timothy E G Krueger, Susan L Dalrymple, Lizamma Antony, Jennifer Dias, Cassandra A Celatka, Amy E Tapper, Maria Kleppe, Mayuko Kanayama, Yuezhou Jing, Valentina Speranzini, Yuzhuo Z Wang, Jun Luo, Bruce J Trock, Samuel R Denmeade, Michael A Carducci, Andrea Mattevi, Hugh Y Rienhoff, John T Isaacs, W Nathaniel Brennen
INTRODUCTION: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes...
April 15, 2024: Prostate
https://read.qxmd.com/read/38618871/sources-of-pharmacokinetic-and-pharmacodynamic-variability-and-clinical-pharmacology-studies-of-antiseizure-medications-in-the-pediatric-population
#43
REVIEW
Patricia D Maglalang, Jiali Wen, Christoph P Hornik, Daniel Gonzalez
Multiple treatment options exist for children with epilepsy, including surgery, dietary therapies, neurostimulation, and antiseizure medications (ASMs). ASMs are the first line of therapy, and more than 30 ASMs have U.S. Food and Drug Administration (FDA) approval for the treatment of various epilepsy and seizure types in children. Given the extensive FDA approval of ASMs in children, it is crucial to consider how the physiological and developmental changes throughout childhood may impact drug disposition. Various sources of pharmacokinetic (PK) variability from different extrinsic and intrinsic factors such as patients' size, age, drug-drug interactions, and drug formulation could result in suboptimal dosing of ASMs...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38612661/applications-of-flow-cytometry-in-drug-discovery-and-translational-research
#44
REVIEW
Sumana Ullas, Charles Sinclair
Flow cytometry is a mainstay technique in cell biology research, where it is used for phenotypic analysis of mixed cell populations. Quantitative approaches have unlocked a deeper value of flow cytometry in drug discovery research. As the number of drug modalities and druggable mechanisms increases, there is an increasing drive to identify meaningful biomarkers, evaluate the relationship between pharmacokinetics and pharmacodynamics (PK/PD), and translate these insights into the evaluation of patients enrolled in early clinical trials...
March 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38607350/bioanalytical-approaches-to-support-the-development-of-antibody-oligonucleotide-conjugate-aoc-therapeutic-proteins
#45
REVIEW
Anthony Murphy, Ryan Hill, Michael Berna
RNA interference (RNAi) is a biological process that evolved to protect eukaryotic organisms from foreign genes delivered by viruses. This process has been adapted as a powerful tool to treat numerous diseases through the delivery of small-interfering RNAs (siRNAs) to target cells to alter aberrant gene expression.Antibody-oligonucleotide conjugates (AOCs) are monoclonal antibodies with complexed siRNA or antisense oligonucleotides (ASOs) that have emerged to address some of the challenges faced by naked or chemically conjugated siRNA, which include rapid clearance from systemic circulation and lack of selective delivery of siRNA to target cells...
April 12, 2024: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/38596468/lung-microdialysis-and-in-vivo-pk-pd-integration-of-cefquinome-against-actinobacillus-pleuropneumoniae-in-a-porcine-experimental-lung-infection-model
#46
JOURNAL ARTICLE
Yuqin Chen, Min Li, Dehai Su, Shiyu Xiong, Youshu Feng, Qin Deng, Huanzhong Ding
This study aim to explore the application of microdialysis in pharmacokinetic (PK) and pharmacodynamic (PD) integration of cefquinome against Actinobacillus pleuropneumoniae in a porcine experimental lung infection model. The model was established via intratracheal inoculation where average bacterial counts (CFU) in the lungs of infected pigs reached 6.57 log10 CFU/g after 3 h. The PK profiles of unbound cefquinome in lung dialysates were determined following intramuscular injection of single doses of 0...
2024: Frontiers in Veterinary Science
https://read.qxmd.com/read/38595918/dosing-optimization-of-rituximab-for-primary-membranous-nephropathy-by-population-pharmacokinetic-and-pharmacodynamic-study
#47
JOURNAL ARTICLE
Hao Liang, Zhenling Deng, Shu Niu, Weijie Kong, Yang Liu, Song Wang, Haiyan Li, Yue Wang, Danxia Zheng, Dongyang Liu
Primary membranous nephropathy (PMN) is the most common cause for adult nephrotic syndrome. Rituximab has demonstrated promising clinical efficacy by random controlled trials and the off-label use is widely adopted in PMN. However, the standard dosage is borrowed from B cell lymphoma treatment with far more antigens and is oversaturated for PMN treatment, accompanied with additional safety risk and unnecessary medical cost. More than 15% serious adverse events were observed under standard dosage and low dose therapies were explored recently...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38593348/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers
#48
JOURNAL ARTICLE
Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, Yingyun Wang, Matthew Holderfield, Ida Aronchik, Ian P Winters, Zeena Salman, Cristina Blaj, Marie Menard, Jens Brodbeck, Zhe Chen, Xing Wei, Michael J Rosen, Yevgeniy Gindin, Bianca J Lee, James W Evans, Stephanie Chang, Zhican Wang, Kyle J Seamon, Dylan Parsons, James Cregg, Abby Marquez, Aidan C A Tomlinson, Jason K Yano, John E Knox, Elsa Quintana, Andrew J Aguirre, Kathryn C Arbour, Abby Reed, W Clay Gustafson, Adrian L Gill, Elena S Koltun, David Wildes, Jacqueline A M Smith, Zhengping Wang, Mallika Singh
UNLABELLED: RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models...
April 9, 2024: Cancer Discovery
https://read.qxmd.com/read/38587080/prophylactic-efficacy-of-an-intranasal-spray-with-2-synergetic-antibodies-neutralizing-omicron
#49
JOURNAL ARTICLE
Xinghai Zhang, Feiyang Luo, Huajun Zhang, Hangtian Guo, Junhui Zhou, Tingting Li, Shaohong Chen, Shuyi Song, Meiying Shen, Yan Wu, Yan Gao, Xiaojian Han, Yingming Wang, Chao Hu, Xiaodong Zhao, Huilin Guo, Dazhi Zhang, Yuchi Lu, Wei Wang, Kai Wang, Ni Tang, Tengchuan Jin, Menglu Ding, Shuhui Luo, Cuicui Lin, Tingting Lu, Bingxia Lu, Yang Tian, Chengyong Yang, Guofeng Cheng, Haitao Yang, Aishun Jin, Xiaoyun Ji, Rui Gong, Sandra Chiu, Ailong Huang
BACKGROUNDAs Omicron is prompted to replicate in the upper airway, neutralizing antibodies (NAbs) delivered through inhalation might inhibit early-stage infection in the respiratory tract. Thus, elucidating the prophylactic efficacy of NAbs via nasal spray addresses an important clinical need.METHODSThe applicable potential of a nasal spray cocktail containing 2 NAbs was characterized by testing its neutralizing potency, synergetic neutralizing mechanism, emergency protective and therapeutic efficacy in a hamster model, and pharmacokinetics/pharmacodynamic (PK/PD) in human nasal cavity...
April 8, 2024: JCI Insight
https://read.qxmd.com/read/38583254/pi3k%C3%AE-and-mtor-dual-inhibitors-design-synthesis-and-anticancer-evaluation-of-3-substituted-aminomethylquinoline-analogues
#50
JOURNAL ARTICLE
Digambar Yevale, Nishith Teraiya, Twinkle Lalwani, Mayur Dalasaniya, Khushal Kapadiya, Rakesh Kumar Ameta, Chetan B Sangani, Yong-Tao Duan
Phosphatidylinositide-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) have recently been identified as potential cancer targets. In our work, a new family of quinoline analogues was designed, developed, and evaluated as dual inhibitors of PI3Kδ/mTOR. The preliminary biological activity analysis led to the discovery of the lead compounds 5h and 5e. Compounds 5h and 5e exhibited excellent anti-tumor potency with IC50 of 0.26 µM and 0.34 µM against Ramos cells, respectively...
March 30, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38578533/model-based-comparison-of-subcutaneous-versus-sublingual-apomorphine-administration-in-the-treatment-of-motor-fluctuations-in-parkinson-s-disease
#51
JOURNAL ARTICLE
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse, Zare Melyan, Jonathan Rubin
The objective of this study was to compare the effectiveness of subcutaneous (SC) and sublingual (SL) formulations of apomorphine for the treatment of motor fluctuations in Parkinson's disease using a pharmacokinetics (PK)/pharmacodynamics (PD) modeling approach. The PK of SC and SL apomorphine are best described by a one-compartment model with first-order absorption and a two-compartment model with delayed absorption, respectively. The PK/PD model relating apomorphine plasma concentrations to the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores was described by a sigmoidal Emax model assuming effective concentration = drug concentration in an effect compartment...
April 5, 2024: Journal of Pharmacokinetics and Pharmacodynamics
https://read.qxmd.com/read/38573940/continuous-evaluation-of-single-dose-moxifloxacin-concentrations-in-brain-extracellular-fluid-cerebrospinal-fluid-and-plasma-a-novel-porcine-model
#52
JOURNAL ARTICLE
T Mariager, J H Terkelsen, M Bue, K Öbrink-Hansen, R Nau, C R Bjarkam, H Nielsen, J Bodilsen
BACKGROUND: Knowledge regarding CNS pharmacokinetics of moxifloxacin is limited, with unknown consequences for patients with meningitis caused by bacteria resistant to beta-lactams or caused by TB. OBJECTIVE: (i) To develop a novel porcine model for continuous investigation of moxifloxacin concentrations within brain extracellular fluid (ECF), CSF and plasma using microdialysis, and (ii) to compare these findings to the pharmacokinetic/pharmacodynamic (PK/PD) target against TB...
April 4, 2024: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/38563414/pharmacokinetics-pharmacodynamics-and-safety-of-fesomersen-a-novel-antisense-inhibitor-of-factor-xi-in-healthy-chinese-japanese-and-caucasian-volunteers
#53
JOURNAL ARTICLE
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
The inhibition of coagulation factor XI (FXI) presents an attractive approach for anticoagulation as it is not expected to increase the risk of clinically relevant bleeding and is anticipated to be at least as effective as currently available anticoagulants. Fesomersen is a conjugated antisense oligonucleotide that selectively inhibits the expression of FXI. The article describes three clinical studies that investigated the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of fesomersen after subcutaneous (s...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38558535/pharmacokinetics-pharmacodynamics-and-safety-of-frunexian-in-healthy-chinese-volunteer-adults-a-randomized-dose-escalation-phase-i-study
#54
JOURNAL ARTICLE
Jia-Yu Zhang, Zou-Rong Ruan, Bo Jiang, Dan-Dan Yang, Jia-Ying Wang, Yin Hu, Yong-Rui Wang, Yan-Mei Wang, Yun-Fei Lin, Ling-Ling Wang, Hong-Gang Lou
The purpose of this study was to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of frunexian (formerly known as EP-7041 and HSK36273) injection, a small molecule inhibitor of activated coagulation factor XI (FXIa), in healthy Chinese adult volunteers. This study was a randomized, placebo- and positive-controlled, sequential, ascending-dose (0.3/0.6/1.0/1.5/2.25 mg/kg/h) study of 5-day continuous intravenous infusions of frunexian. Frunexian administration exhibited an acceptable safety profile with no bleeding events...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38558445/pharmacokinetic-and-pharmacodynamic-evaluation-of-nitrofurantoin-against-escherichia-coli-in-a-murine-urinary-tract-infection-model
#55
JOURNAL ARTICLE
Marit Gaastra Maaland, Lotte Jakobsen, Luca Guardabassi, Niels Frimodt-Møller
The antimicrobial agent nitrofurantoin is becoming increasingly important for treatment of urinary tract infections (UTIs) due to widespread occurrence of multidrug-resistant Escherichia coli. Despite many years of use, little data on nitrofurantoin pharmacokinetics (PK) or -dynamics (PD) exist. The objective of this study was to (i) evaluate the pharmacokinetics of nitrofurantoin in a mouse model and (ii) use that data to design an in vivo dose fractionation study in an experimental model of UTI with E. coli for determination of the most predictive PK/PD index...
April 1, 2024: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://read.qxmd.com/read/38532525/quantitative-evaluation-of-trastuzumab-deruxtecan-pharmacokinetics-and-pharmacodynamics-in-mouse-models-of-varying-degrees-of-her2-expression
#56
JOURNAL ARTICLE
Christina Vasalou, Theresa A Proia, Laura Kazlauskas, Anna Przybyla, Matthew Sung, Srinivas Mamidi, Kim Maratea, Matthew Griffin, Rebecca Sargeant, Jelena Urosevic, Anton I Rosenbaum, Jiaqi Yuan, Krishna C Aluri, Diane Ramsden, Niresh Hariparsad, Rhys D O Jones, Jerome T Mettetal
Trastuzumab deruxtecan (T-DXd; DS-8201; ENHERTU®) is a human epithelial growth factor receptor 2 (HER2)-directed antibody drug conjugate (ADC) with demonstrated antitumor activity against a range of tumor types. Aiming to understand the relationship between antigen expression and downstream efficacy outcomes, T-DXd was administered in tumor-bearing mice carrying NCI-N87, Capan-1, JIMT-1, and MDA-MB-468 xenografts, characterized by varying HER2 levels. Plasma pharmacokinetics (PK) of total antibody, T-DXd, and released DXd and tumor concentrations of released DXd were evaluated, in addition to monitoring γΗ2AX and pRAD50 pharmacodynamic (PD) response...
March 26, 2024: CPT: Pharmacometrics & Systems Pharmacology
https://read.qxmd.com/read/38529396/safety-tolerability-pharmacokinetics-and-pharmacokinetic-pharmacodynamic-modeling-of-cetagliptin-in-patients-with-type-2-diabetes-mellitus
#57
JOURNAL ARTICLE
Chen Zhou, Sufeng Zhou, Jie Wang, Lijun Xie, Zhanhui Lv, Yuqing Zhao, Lu Wang, Huan Luo, Daosheng Xie, Feng Shao
AIMS: To evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cetagliptin (CAS number:2243737-33-7) in Chinese patients with type 2 diabetes mellitus (T2DM). A population PK/PD model was developed to quantify the PK and PD characteristics of cetagliptin in patients. MATERIALS AND METHODS: 32 Chinese adults with T2DM were enrolled in this study. The subjects were randomly assigned to receive either cetagliptin (50 mg or 100 mg), placebo, or sitagliptin (100 mg) once daily for 14 days...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38529184/establishment-of-a-pharmacokinetics-and-pharmacodynamics-model-of-schisandra-lignans-against-hippocampal-neurotransmitters-in-ad-rats-based-on-microdi-alysis-liquid-chromatography-mass-spectrometry
#58
JOURNAL ARTICLE
Jinpeng Zhang, Xinyuan Cui, Shuo Zhao, Zenghui Chang, Junshuo Zhang, Yufeng Chen, Jiale Liu, Guohao Sun, Yiyuan Wang, Yuanyuan Liu
Objective: Our previous studies substantiated that the biological activity of Schisandra chinensis lignans during the treatment of Alzheimer's disease (AD) was mediated by neurotransmitter levels, and 15 of its active components were identified. However, the pharmacokinetic and pharmacodynamic relationship of Schisandra chinensis lignans has been less studied. The objective of this study was to investigate the relationship between the pharmacokinetics and pharmacodynamics of Schisandra chinensis lignans in the treatment of AD, and to establish a pharmacokinetic-pharmacodynamic (PK-PD) model...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38528813/population-pharmacokinetic-pharmacodynamic-modeling-of-serum-biomarkers-as-predictors-of-tumor-dynamics-following-lenvatinib-treatment-in-patients-with-radioiodine-refractory-differentiated-thyroid-cancer-rr-dtc
#59
JOURNAL ARTICLE
Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, Bojan Lalovic, Taro Hihara, Taisuke Hoshi, Yasuhiro Funahashi, Jagadeesh Aluri, Osamu Takenaka, Sanae Yasuda, Ziad Hussein
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor (FGF) receptors 1-4, platelet-derived growth factor receptor-α (PDGFRα), KIT, and RET that have been implicated in pathogenic angiogenesis, tumor growth, and cancer. The primary objective of this work was to evaluate, by establishing quantitative relationships, whether lenvatinib exposure and longitudinal serum biomarker data (VEGF, Ang-2, Tie-2, and FGF-23) are predictors for change in longitudinal tumor size which was assessed based on data from 558 patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) receiving either lenvatinib or placebo treatment...
March 26, 2024: CPT: Pharmacometrics & Systems Pharmacology
https://read.qxmd.com/read/38526820/an-integrated-strategy-to-evaluate-active-substances-of-astragali-radix-carthami-flos-combination-on-the-treatment-of-cerebral-ischemia-reperfusion-injury-based-on-tqsm-polypharmacokinetics-and-pharmacodynamics
#60
JOURNAL ARTICLE
Qiang Zeng, Chang Li, Shouchao Xu, Yu He
As a classic herb pair, Astragali Radix-Carthami Flos (AR-CF) has revealed good biological activity in the treatment of cerebral ischemia/reperfusion injury (CI/RI), which remained to be further clarified together with the underlying efficacy related compounds for material basis. In this study, the nine formulations were obtained by L9 (34) orthogonal array design of four active fractions (saponin and flavonoid extracted from AR, safflower yellow and safflower red extracted from CF). The concentrations of eleven components and the levels of four biochemical indicators in rat plasma were continuously detected after intragastric administration of nine formulations, respectively...
December 15, 2023: Journal of Food and Drug Analysis
keyword
keyword
48137
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.